Malaria Parasite Culture and Strain Characterization

MMV019719, MMV665924, and MMV897615 were freely available as part of the Medicines for Malaria Venture’s (MMV) Malaria Box. Triacsin C was purchased from Sigma-Aldrich (St. Louis, MO, ref. T4540). The 3D7 P. falciparum strain was originally obtained through MR4 as part of the BEI Resources Repository, NIAID, NIH: 3D7, MRA-102, deposited by D. J. Carucci. We also used 3D7- IG06 (a fast-growing 3D7 clone)^{64 (link)} donated by Daniel Goldberg and Dd2-Polδ²³ donated by Marcus Lee. The Malawi parasites (CF04.008 10B and CF04.009 6D and 1 G, two different patient isolates that were subcloned after culture adaption) were kindly donated by Danny Milner^{26 (link)}. Parasites were cultured by standard methods^{65 (link)} in RPMI 1640 medium supplemented with 28 mM NaHCO₃, 25 mM HEPES, 400 μM hypoxanthine, 25 μg/mL gentamicin, and 0.5% AlbuMAX II (Life Technologies, Carlsbad, CA 11021-045). The human erythrocytes were sourced ethically, and their research use was in accord with the terms of approved protocol.

Free full text: Click here

Bopp S., Pasaje C.F., Summers R.L., Magistrado-Coxen P., Schindler K.A., Corpas-Lopez V., Yeo T., Mok S., Dey S., Smick S., Nasamu A.S., Demas A.R., Milne R., Wiedemar N., Corey V., Gomez-Lorenzo M.D., Franco V., Early A.M., Lukens A.K., Milner D., Furtado J., Gamo F.J., Winzeler E.A., Volkman S.K., Duffey M., Laleu B., Fidock D.A., Wyllie S., Niles J.C, & Wirth D.F. (2023). Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formation. Nature Communications, 14, 1455.

Publication 2023

Triacsin C AlbuMAX II

Adaption Clone Erythrocytes Gentamicin Hepes Human Hypoxanthine Malaria Medicines Nahco3 Parasites Patient Strain Triacsin c

Corresponding Organization :

Other organizations : Harvard University, Massachusetts Institute of Technology, Columbia University Irving Medical Center, Wellcome Centre for Anti-Infectives Research, University of Dundee, Broad Institute, University of California, San Diego, GlaxoSmithKline (Spain), Medicines for Malaria Venture

Top 5 similar protocols

Variable analysis

independent variables

MMV019719
MMV665924
MMV897615
Triacsin C

dependent variables

Parasite growth and proliferation of 3D7 P. falciparum strain
Parasite growth and proliferation of 3D7-IG06 clone
Parasite growth and proliferation of Dd2-Polδ
Parasite growth and proliferation of Malawi parasites (CF04.008 10B, CF04.009 6D, and CF04.009 1G)

control variables

RPMI 1640 medium composition (28 mM NaHCO3, 25 mM HEPES, 400 μM hypoxanthine, 25 μg/mL gentamicin, 0.5% AlbuMAX II)
Human erythrocytes (sourced ethically and used in accordance with approved protocol)

positive controls

3D7 P. falciparum strain (obtained through MR4 as part of the BEI Resources Repository, NIAID, NIH)

negative controls

Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!